The Next Cancer Bestseller?  

Oleh:

Langreth, Robert

Jenis: Article from Bulletin/Magazine
Dalam koleksi: Forbes Asia vol. 5 no. 8 (May 2009), page 48-49.
Topik: Novartis; Kidney Cancer Drug; Experiments; Drug Industry; Biotech Company

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: FF5.1 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Novartis has ambitious plans for its new kidney cancer drug. In an unusual move, it plans to test Afinitor simultaneously on five other tumor types, including stomach, breast and neuroendocrine tumors (the type Apple's Steve Jobs has suffered from). The eight trials - some under way and others scheduled to start later this year - will involve 5,000 patients in 35 countries. It's a risky business move for Novartis, too. The drug's science is obscure. Racing againts Novartis are such competitors as Merck and Wyeth.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali